Europe Genetic Testing Market Forecast 2022-2030
KEY FINDINGS
The Europe genetic testing market is estimated to record a CAGR of 10.04% during the forecast period, 2022-2030. Market growth is driven by the presence of major biotechnology and medical companies, easy access to government subsidies for medical procedures, and efficient healthcare systems.
MARKET INSIGHTS
The Europe genetic testing market growth analysis includes the assessment of Russia, Spain, the United Kingdom, Germany, Nordic Countries, France, Italy, and Rest of Europe. In Spain, the requirement for genetic testing equipment is growing with many major companies in the domain. Also, genetic counseling is another space for patients. Companies are actively engaging genetic counselors and clinical geneticists to provide genetic information to the public. In addition, the increasing awareness of genetic testing is set to positively affect the market growth in Spain.
There are about 560,000 births per year in Italy, thereby increasing the potential for prenatal testing nationally. Moreover, 80% of the Italian biotech sector consists of small and micro companies, which influences the overall market growth.
Moreover, Russia plans to initiate special digital genetic passports consisting of genome sequencing of every citizen of the country. According to the recent statements made by the Russian federal government and some analysts, the data could be further used to form genetic profiles and identify susceptibility to diseases. These decisions will positively influence market growth by increasing the demand for genetic testing.
COMPETITIVE INSIGHTS
Some key market players in the region include Roche Diagnostics Inc, Perkinelmer Inc, Bio-Rad Laboratories, Abbott Laboratories, Qiagen, etc.
Our report offerings include:
Explore key findings of the overall market
Strategic breakdown of market dynamics (Drivers, Restraints, Opportunities, Challenges)
Market forecasts for a minimum of 9 years, along with 3 years of historical data for all segments, sub-segments, and regions
Market Segmentation cater to a thorough assessment of key segments with their market estimations
Geographical Analysis: Assessments of the mentioned regions and country-level segments with their market share
Key analytics: Porter’s Five Forces Analysis, Vendor Landscape, Opportunity Matrix, Key Buying Criteria, etc.
Competitive landscape is the theoretical explanation of the key companies based on factors, market share, etc.
Company profiling: A detailed company overview, product/services offered, SCOT analysis, and recent strategic developments
- 1. Research Scope & Methodology
- 1.1. Study Objectives
- 1.2. Scope Of Study
- 1.3. Methodology
- 1.4. Assumptions & Limitations
- 2. Executive Summary
- 2.1. Market Size & Estimates
- 2.2. Market Overview
- 3. Market Dynamics
- 3.1. Key Drivers
- 3.1.1. Advancements In Biotechnology
- 3.1.2. Growth In Prenatal Testing
- 3.1.3. Rise In Direct-to-consumer Genetic Testing
- 3.1.4. Genetic Testing Helps In Determining Medication Dosage
- 3.2. Key Restraints
- 3.2.1. Expensive Cost Of Treatment
- 3.2.2. Government Regulation And Legislation
- 4. Key Analytics
- 4.1. Impact Of Covid-19 On Genetic Testing Market
- 4.2. Key Market Trends
- 4.3. Porter’s Five Forces Analysis
- 4.3.1. Buyers Power
- 4.3.2. Suppliers Power
- 4.3.3. Substitution
- 4.3.4. New Entrants
- 4.3.5. Industry Rivalry
- 4.4. Opportunity Matrix
- 4.5. Vendor Landscape
- 4.6. Value Chain Analysis
- 4.7. Key Buying Criteria
- 4.8. Regulatory Framework
- 5. Market By Type
- 5.1. Prenatal And Newborn Testing
- 5.2. Diagnostic Testing
- 5.3. Predictive & Presymptomatic Testing
- 5.4. Carrier Testing
- 5.5. Pharmacogenomic Testing
- 5.6. Other Types
- 6. Market By Technology
- 6.1. Molecular Testing
- 6.2. Cytogenetic Testing
- 6.3. Biochemical Testing
- 7. Market By Application
- 7.1. Genetic Disease Diagnosis
- 7.2. Cancer Diagnosis
- 7.3. Cardiovascular Disease Diagnosis
- 7.4. Other Applications
- 8. Market By Disease
- 8.1. Cancer
- 8.2. Cystic Fibrosis
- 8.3. Huntington’s Disease
- 8.4. Sickle Cell Anaemia
- 8.5. Duchenne Muscular Dystrophy
- 8.6. Alzheimer’s Disease
- 8.7. Rare Diseases
- 8.8. Thalassemia
- 8.9. Other Diseases
- 9. Geographical Analysis
- 9.1. Europe
- 9.1.1. Market Size & Estimates
- 9.1.2. Key Growth Enablers
- 9.1.3. Key Challenges
- 9.1.4. Key Players
- 9.1.5. Country Analysis
- 9.1.5.1. United Kingdom
- 9.1.5.2. Germany
- 9.1.5.3. France
- 9.1.5.4. Spain
- 9.1.5.5. Italy
- 9.1.5.6. Russia
- 9.1.5.7. Nordic Countries
- 9.1.5.8. Rest Of Europe
- 10. Competitive Landscape
- 10.1. Key Strategic Developments
- 10.1.1. Mergers & Acquisitions
- 10.1.2. Product Launches & Developments
- 10.1.3. Partnerships & Agreements
- 10.1.4. Business Expansions & Divestitures
- 10.2. Company Profiles
- 10.2.1. 23&Me Inc
- 10.2.2. Abbott Laboratories
- 10.2.3. Bgi Group
- 10.2.4. Bio-rad Laboratories
- 10.2.5. Csl Limited
- 10.2.6. Decode Genetics
- 10.2.7. Elitech Group
- 10.2.8. Eurofins Scientific
- 10.2.9. Illumina Inc
- 10.2.10. Luminex Corporation
- 10.2.11. Myriad Genetics Inc
- 10.2.12. Perkinelmer Inc
- 10.2.13. Qiagen
- 10.2.14. Quest Diagnostics Inc
- 10.2.15. Roche Diagnostics Inc
Research Assistance
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.
Download eBook